Effect of mirtazapine on craving in cocaine-dependent patients
No Thumbnail Available
Date
2022
Journal Title
Journal ISSN
Volume Title
Publisher
Springer
Abstract
Description
Drug craving is the intense desire to consume drugs of abuse that promote compulsive drug use and cause drug relapse, following long-term drug withdrawal. Antidepressants like mirtazapine could be a real alternative therapy to attenuate or prevent cocaine withdrawal symptoms and drug craving. In the present study, we examined the efficacy of mirtazapine on cocaine craving in cocaine-detoxified patients during its maintenance phase. A two-arm randomized, placebo-controlled, double-blind clinical trial was scheduled for a complete 12-week period. A total of 64 cocaine-dependent individuals were randomly allocated into two groups: the placebo group (n = 32) and the mirtazapine (n = 32) groups. Both Cocaine Craving Questionnaire (CCQ-G) and the Symptom Check List 90 (SCL-90-R) were used to assess cocaine craving and the psychopathological status of patients, respectively. Assessments were performed once a week for 12 weeks during the study. Mirtazapine (30 mg/kg) was given daily during the 12 weeks of enduring drug
withdrawal. A daily dosing regimen of mirtazapine (30 mg/kg) for 12 weeks significantly decrease the cocaine craving, cocaine use, and some psychiatric symptoms which included depression, anxiety, and mood-negative states along the 12 weeks that endured the study. These data suggest that mirtazapine given to cocaine-dependent patients for 12 weeks of drug withdrawal significantly decreases and controls cocaine-craving behavioral alterations. Furthermore, the present study demonstrates that mirtazapine reduces efficiently some co-morbid psychiatric symptoms that appear during cocaine withdrawal.
These results argue in favor of using mirtazapine for treating cocaine addiction, reducing comorbid cocaine-withdrawal symptomology, and relieving drug craving in addicted subjects. Clinical trial number: NCT ID: NCT01949571.